During the 56th ERA-EDTA Congress, only on June 13, 2019, a new exclusive initiative will be held, the first CEPD (Continuous Education and Professional Development).

a unique opportunity for professional development with tailored courses given by top European experts in the field.

www.era-edta.org
HALL G1 08:45 - 12:25

CEPD 1

**Primary and Secondary Glomerulonephritis, vasculitis and auto-immune diseases**

Chairs: Rosanna Coppo, Turin, Italy
         Vladimir Tesar, Prague, Czech Republic

Focal and segmental glomerulosclerosis (FSGS)
Claudio Ponticelli, Milan, Italy

Membranous Nephropathy
Jack Wetzels, Nijmegen, The Netherlands

IgA Nephropathy
Rosanna Coppo, Turin, Italy

New directions in the treatment of ANCA-associated nephritis
Marten Segelmark, Lund, Sweden

Lupus Nephritis
Vladimir Tesar, Prague, Czech Republic

HALL G2A 08:45 - 12:25

CEPD 2

**CKD**

Chairs: Raymond Vanholder, Ghent, Belgium
         Andrzej Więcek, Katowice, Poland

Concept and global burden of CKD: current status and beyond
Ron Gansevoort, Groningen, The Netherlands

What is the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+)?
Marie Evans, Stockholm, Sweden

Anaemia management in CKD patients: past, present and the future
Andrzej Więcek, Katowice, Poland

Optimal timing and method for RRT proposed to CKD patients
Raymond Vanholder, Ghent, Belgium
Scientific Programme

HALL G2B

CEPD 3

Hypertension, Diabetes and CV Disease in CKD

Chairs: Francesca Mallamaci, Reggio Calabria, Italy
Esteban Porrini, La Laguna (Tenerife), Spain

Inflammation in CKD: cures at last?
Danilo Fliser, Homburg/Saar, Germany

Progress in the prevention and cure of diabetic nephropathy
Lucia Del Vecchio, Lecco, Italy

Prognosis by risk calculators in CKD and in ESRD
Friedo W. Dekker, Leiden, The Netherlands

LV dysfunction with preserved ejection fraction in CKD: epidemiology, mechanism(s) and therapy
Patrick Rossignol, Vandœuvre-lès-Nancy, France

HALL F1

CEPD 4

Bone Mineral disorders in CKD

Chairs: Markus Ketteler, Stuttgart, Germany
Marc Vervloet, Amsterdam, The Netherlands

How to prevent fractures in CKD?
Pieter Evenepoel, Leuven, Belgium

Are we inducing adynamic bone disease, and is that a problem?
Mathias Haarhaus, Stockholm, Sweden

Is FGF23 outdated?
Marc Vervloet, Amsterdam, The Netherlands

Don’t forget our old friend Vitamin D
Justine Bacchetta, Lyon, France
HALL A1

CEPD 5

Genetic Diseases and Rare Diseases

Chairs: Olivier Devuyst, Zurich, Switzerland
       Anna Koettgen, Freiburg, Germany

Genetic studies as part of pre-transplant evaluation
Jan Halbritter, Leipzig, Germany

Genomic studies in adult CKD patients
Ali G. Gharavi, New York, NY, U.S.A.

Recent GWAS of kidney function markers
Anna Koettgen, Freiburg, Germany

Polycystic kidney disease: new genes and clinical studies
Olivier Devuyst, Zurich, Switzerland

Update on tubular and tubulointerstitial diseases
Detlef Bockenhauer, London, United Kingdom

HALL A2

CEPD 6

Basic and Transitional Nephrology

Chairs: Annette Bruchfeld, Stockholm, Sweden
       Paola Romagnani, Florence, Italy

Single cell transcriptomics of solid tissues: choices and challenges
Sanjay Jain, Saint Louis, MO, U.S.A.

The new age of kidney imaging
Nicole Endlich, Greifswald, Germany

Gene editing and new models of kidney diseases
Ariela Benigni, Bergamo, Italy

How we survive acute injury and develop chronic disease: kidney, heart and liver not so different after all
Paola Romagnani, Florence, Italy

Optogenetic control of inflammation in acute kidney injury
Mark D. Okusa, Charlottesville, VA, U.S.A.
Scientific Programme

HALL A3

CEPD 7

Nephropathology

Chairs: Pablo Cannata-Ortiz, Madrid, Spain
       Helen Liapis, Little Rock, AR, U.S.A.

Renal biopsy handling: improving diagnosis in the pre-analytical phase
Pablo Cannata-Ortiz, Madrid, Spain

FSGS on renal biopsy: why an integrated approach to diagnosis is necessary
Laura Barisoni, Durham, NC, U.S.A.

Atypical post-streptococcal GN and complement
Isabelle Brocheriou, Paris, France

Diabetic Nephropathy versus Kidney Diseases in Diabetics
Loreto Gesualdo, Bari, Italy

The histopathologic spectrum of obesity-related glomerulopathy
Helen Liapis, Little Rock, AR, U.S.A.

Update on fibrillary and immunotactoid glomerulopathy
Sándor Turkevi-Nagy, Szeged, Hungary

Renal side effects of novel anti-cancer drugs
Joris Roelofs, Amsterdam, The Netherlands

How to diagnose chronic TCMR in kidney transplants: Banff and the evidence
Marion Rabant, Paris, France
HALL A1
CEPD 8

**Haemodialysis and Vascular Access**

Chairs: Peter J. Blankestijn, Utrecht, The Netherlands
Rukshana Shroff, London, United Kingdom

**Vascular access**

- Prevention and treatment of central venous catheter infections
  **Laura Labriola**, Brussels, Belgium

- New developments in vascular access: what can we expect for the future?
  **Joris Rotmans**, Leiden, The Netherlands

- Guidelines on vascular access creation and management
  **Evi Nagler**, Ghent, Belgium

**Haemodialysis**

- Dialysis care: personalized or universal?
  **Andrew Davenport**, London, United Kingdom

- HDF in children: what can we learn from paediatric studies
  **Rukshana Shroff**, London, United Kingdom

- How to increase home and self-care haemodialysis?
  **Sandip Mitra**, Manchester, United Kingdom
Scientific Programme

HALL G2A
13:00 - 16:40
CEPD 9

Renal Transplantation

Chairs: Daniel Abramowicz, Antwerp, Belgium
Bruno Watschinger, Vienna, Austria

Can this person receive a kidney: what is the minimal workup that should be done in a healthy kidney transplant candidate?
Luuk Hilbrands, Nijmegen, The Netherlands

How long should a patient with previous cancer wait before being wait-listed?
Bruno Watschinger, Vienna, Austria

How can I evaluate this extended criteria kidney according to ECD, DCD, KDRI?
Umberto Maggiore, Parma, Italy

How should I prevent CMV disease and BK PVN in 2019?
Rachel Hellemans, Antwerp, Belgium

How should I personalise maintenance therapy according to donor/recipient factors?
Klemens Budde, Berlin, Germany

HALL G2B
13:00 - 16:40
CEPD 10

AKI

Chairs: Andreas Kribben, Essen, Germany
Mehmet Sukru Sever, Istanbul, Turkey

Volume management throughout the course of AKI: Risk – Oliguria – RRT – Polyuria
Wim Van Biesen, Ghent, Belgium

AKI in geriatric population and in frailty
Norbert Lameire, Ghent, Belgium

AKI in austere environments
Valerie A. Luyckx, Zurich, Switzerland

Recent clinical trials and update in AKI
Andreas Kribben, Essen, Germany
HALL F1       13:00 - 16:40

CEPD 11

Peritoneal Dialysis

Chairs: Andrew Davenport, London, United Kingdom
       Olof Heimbürger, Stockholm, Sweden

PD catheter insertion and complications
Victoria R. Briggs, Sheffield, United Kingdom

How to prescribe APD
Carl M. Öberg, Lund, Sweden

Prevention, diagnostics and treatment of peritonitis
Anabela Rodrigues, Porto, Portugal

Update on PD solutions
Monika Lichodziejewska-Niemierko, Gdańsk, Poland

Changes in peritoneal structure and function with time on PD
Johann Morelle, Brussels, Belgium

HALL A1       13:00 - 16:40

CEPD 12

Electrolytes and urolithiasis

Chairs: Ewout Hoorn, Rotterdam, The Netherlands
        Carsten Wagner, Zurich, Switzerland

Disorders of sodium and water
Ewout Hoorn, Rotterdam, The Netherlands

Hypo- and Hyperkalemia
Felix Knauf, Berlin, Germany

Disorders of calcium and magnesium
Pascal Houillier, Paris, France

Acid-Base disturbances and stones (case-based)
Nilufar Mohebbi, Zurich, Switzerland
Stephen Walsh, London, United Kingdom

Stones and electrolytes (case-based)
Philippe Jaeger, London, United Kingdom
Scientific Programme

HALL A2

CEPD 13

ERA-EDTA Registry

Chairs: Kitty Jager, Amsterdam, The Netherlands  
Ziad Massy, Paris, France

Different flavours in RCTs and their analyses  
Giovanni Luigi Tripepi, Reggio Calabria, Italy

Pros and cons of surrogate outcomes in RCTs  
Kitty Jager, Amsterdam, The Netherlands

Mendelian randomization to enable causal inference in observational studies  
Friedo W. Dekker, Leiden, The Netherlands

Directed acyclic graphs (DAGs) to address confounding  
Natalie Staplin, Oxford, United Kingdom